An 8-year retrospective analysis of invasive Aspergillus stomatitis in neutropenic patients with acute leukemia was performed to characterize the epidemiology and clinical features of the infection. Twelve cases of invasive Aspergillus stomatitis were identified with both clinicohistological and microbiological evidence, and the majority of cases were caused by Aspergillus flavus (10 [83%] of 12 patients). The infection was strongly suspected when a neutropenic patient developed persistent fever without a known source, symptoms of gingival pain and facial swelling, and a solitary ulcerating lesion of mucogingiva covered with a gray necrotic pseudomembrane. Aspergillus stomatitis was diagnosed a median 23 days after admission. In all 12 patients, the diagnosis was made during the period of neutropenia. Ten patients (83%) were treated with amphotericin B and surgery and survived with recovery of neutrophils. Two patients died, and disseminated aspergillosis was identified in 1 patient.
Invasive Aspergillus infection is a major problem in patients with acute leukemia and occurs as a consequence of intensive chemotherapy, which produces prolonged neutropenia [1, 2] . The infection is life threatening, with an associated mortality that ranges from 50% to 100% despite antifungal therapy [1] [2] [3] [4] [5] [6] . The lung is the most common site of invasive Aspergillus infection, and primary infection of nonpulmonary sites commonly affecting the skin or the paranasal sinuses has been described elsewhere [2] [3] [4] [5] [6] [7] . The liver, spleen, brain, heart, pericardium, and other body sites are involved in a minority of cases [7] . The more common species of Aspergillus causing invasive disease include Aspergillus fumigatus, A. flavus, A. niger, A. terreus, and A. nidulans [2] [3] [4] [5] [6] [7] ; in particular, A. fumigatus accounts for ∼90% of cases of invasive aspergillosis [7] .
The number of reported cases of primary invasive oral aspergillosis is small, and a limited amount of information was detailed in these cases, with no review describing multiple cases at 1 institution over an extended period of time [8] [9] [10] [11] . Therefore, the typical clinical patterns of the infection have never been clearly documented. We described elsewhere [12] our preliminary experience with invasive oral Aspergillus infection in patients with leukemia. Here, we report the results of an 8-year retrospective analysis of 12 definite cases of invasive Aspergillus stomatitis in patients with acute leukemia at the Hiroshima Red Cross and Atomic Bomb Survivors Hospital, Hiroshima, Japan. To our knowledge, this is the largest currently reported series on invasive oral aspergillosis. We evaluated each case in detail, emphasizing clinical characteristics, treatment, outcome, and epidemiologic features to determine any unique aspects of the infection in immunocompromised hosts.
PATIENTS AND METHODS
Case patient definition. Beginning in 1991, all pa- tients hospitalized for acute leukemia were routinely examined by oral surgeons when they developed stomatitis during neutropenia (absolute neutrophil count !500 cells/mL). These neutropenic patients were isolated in laminar air-flow rooms in a hematology ward and received sterile food. To prevent the development of invasive fungal infections, prophylactic medication was administered. The patients received iv fluconazole (200-400 mg/day) and mouthwash with amphotericin B suspension (100 mg/mL) during neutropenia. Together with these agents, administration of itraconazole capsules started at 100 mg/day in 1994 and increased to 200 mg/day in 1997. Cases of Aspergillus stomatitis were defined by histopathological finding of hyphae in biopsy specimens from the oral cavity in combination with microbiological evidence of an Aspergillus species in the same material. The date of diagnosis of the infection was the day on which an oral biopsy specimen with typical histopathological change was obtained. Clinical findings. Clinical records of patients with invasive Aspergillus stomatitis were reviewed, and the following information was collected: underlying illness; duration of fever; duration of neutropenia; duration of antibiotic therapy; signs and symptoms referable to the orofacial region; antifungal medication (duration, total dosage, and concomitant use of у2 therapies); findings at biopsy and surgery; and outcome. Information of oral conditions such as periodontal disease and foci in the mandible or maxilla were recorded. In addition, in fatal cases, autopsy records were reviewed.
RESULTS
In the 8 years from January 1991 through December 1998, 12 cases of invasive Aspergillus stomatitis were identified, and the clinical characteristics of these patients are presented in table 1. Six patients were male, and 6 patients were female. The median age of the patients was 55 years (range, 21-78 years). The types of underlying leukemia included acute myelogenous leukemia (11 patients) and mixed lineage leukemia (1 patient). Eleven patients were admitted for induction chemotherapy and 1 patient for relapse of leukemia. Although stomatitis secondary to cytotoxic treatments is a frequent finding in neutropenic patients with acute leukemia, physical findings of Aspergillus stomatitis at biopsy revealed that the disease appeared to have distinctive stages (table 1) . This sequence of the invasive infection began as a violaceous discoloration of the gingiva that rapidly progressed to a necrotic ulcer surfaced by a gray pseudomembrane with a rim of violaceous mucosa, advancing relentlessly to cause destruction of alveolar bone and facial muscles (figure 1). Aspergillus infection affected all sites of the gingiva without a specific predilection and usually developed as solitary foci. All 12 patients were febrile before and at the time of diagnosis and complained of great gingival pain and facial swelling. Excessive salivation and pain on swallowing were noted in 9 patients (75%) and 4 patients (33%), respectively (table 1) .
Dental histories revealed that 11 patients had periodontal disease, including marginal periodontitis and gingivitis, 8 had periapical foci, and 1 had a denture decubitic ulcer. In these 12 cases, invasive Aspergillus stomatitis started on the marginal gingiva, but not on the tongue or buccal mucosa, and spread to the adjacent tissues.
Invasive Aspergillus stomatitis was diagnosed by examination of biopsy tissue specimens a median of 23 days (range, 14-38 days) after admission (table 2). All patients with infection were severely neutropenic because of antileukemic chemotherapy for 18-65 days (median, 29 days). Aspergillus infection in patients with neutropenia was diagnosed a median of 11 days (range, 7-26 days) after the onset of neutropenia. Fungal isolates from biopsy specimens were forwarded to the Research Center for Pathogenic Fungi and Microbial Toxicoses, Chiba University, Chiba, Japan, for species identification. Of the 12 patients with invasive Aspergillus stomatitis, 10 (83%) were infected with A. flavus and 2 (17%) were infected with A. terreus (table 2) . During the same period, 18 cases of confirmed invasive pulmonary aspergillosis were identified on the basis of postmortem examinations: A. fumigatus was isolated in 14, A. flavus in 3, and A. terreus in 1 case patient, respectively. Treatment regimens varied, as shown in table 2. All 12 patients received iv amphotericin B, total doses ranging from 330 mg to 2150 mg. Seven patients (58%) were treated with amphotericin B before the diagnosis of invasive Aspergillus stomatitis, because of persistent fever during neutropenia. Nine patients were given amphotericin B in combination with 5-fluorocytosine (5-FC). Three patients received amphotericin B in combination with 5-FC and itraconazole, because itraconazole was available in our institution from 1994. All patients received granulocyte colony-stimulating factor to facilitate neutrophil production along with antifungal medication. This growth factor was given at 150-300 mg per day for 6-23 days (median, 13 days) during neutropenia, and neutrophils returned in 10 of 12 patients. In addition, topical application of iodine glycerin (10% iodine) to the affected areas was performed once a day.
Overall, 10 patients underwent surgical management, including debridement of necrotic mucosa and removal of necrotic bone. These patients survived and were discharged without further evidence of the infection (table 2). Surgical treatment was performed in 7 patients with advanced aspergillosis when their hematologic status, especially neutrophil count, improved. Three patients underwent surgical management during neutropenia because aspergillosis was at an early stage. Two patients who did not undergo surgical intervention because of rapid progression of Aspergillus infection without recovery of neutrophil count died, developing noma-like infections. A postmortem examination was performed on 1 of the 2 patients and revealed evidence of invasive Aspergillus dissemination to pulmonary sites.
The annual incidence of invasive Aspergillus stomatitis ranged from 0% to 7.8% (median, 2.1%) among individual patients admitted у1 times during each calendar year for treatment of leukemia. Because each patient had different neutropenic episodes, which are critical risk factors, we also calculated the rates based on a denominator of neutropenic episodes in the patients. The presence of neutropenia for a period of у10 days' duration was used as 1 episode. The number of cases per episode ranged from 0% to 3.3% (median, 1.1%; table 3).
DISCUSSION
Invasive oral aspergillosis can be primary or secondary in origin, and the majority of cases reported were the latter, which represented extension from rhinosinus Aspergillus infection [8, [13] [14] [15] . In 1970, Young et al. [11] first described oropharyngeal aspergillosis in 3 patients as a distinctive type of invasive aspergillosis, although, the details of primary sites, underlying diseases, risk factors, and treatments in their cases were not clear. More recently, 3 cases of primary invasive oral aspergil- losis, 2 in patients with acute leukemia and 1 with AIDS, have been reported elsewhere [8] [9] [10] . Only 2 of the 3 cases showed both histological and microbiological evidence to confirm Aspergillus infection [8, 10] . In the present study, 12 definite cases of invasive Aspergillus stomatitis are reported; these cases were identified by a retrospective review of patients with acute leukemia who had been hospitalized at the Hiroshima Red Cross and Atomic Bomb Survivors Hospital over an 8-year period (January 1991-December 1998). Of these 12 cases, 11 infections were confined to the orofacial area, whereas 1 developed into fatal disseminated fungal disease. A. flavus was the most frequent cause of Aspergillus stomatitis, causing 9 cases of localized invasive disease and 1 of disseminated infection, resulting in 10 (83%) of 12 cases. In contrast, A. fumigatus, which is the most common cause of invasive aspergillosis [7] , was not identified in the present cases. In other reported cases, A. flavus was also the causative organism for invasive stomatitis [8, 10] . During the same period, A. fumigatus was the most frequent cause of invasive pulmonary aspergillosis (14 [78%] of 18 patients) in our institution. These findings substantiate the strong association between A. flavus and invasive Aspergillus stomatitis. The high incidence of Aspergillus stomatitis caused by A. flavus probably relates to the larger diameters of A. flavus conidia compared to those of other aspergilli conidia, which could determine where they were predominantly deposited in the oral tissues [14] . In addition, we suspect that contaminated food might be an important determinant of the predominant outbreak of Aspergillus stomatitis due to A. flavus. Bouakline et al. [16] recently demonstrated the Aspergillus contamination of food served to patients in hematology wards, which suggests that food is a potential source of fungal exposure for neutropenic patients.
Neutropenia and the duration of neutropenia are known risk factors for invasive aspergillosis [1, 5, 6, 14] . This was also evident in patients in our institution, where all 12 patients with invasive Aspergillus stomatitis were neutropenic, with median neutropenic duration of 29 days (range, 18-65 days).
Previous studies suggested that prior or present viral or bacterial infections of the affected sites could enhance susceptibility to Aspergillus infection during neutropenia because of mucosal cell abnormalities and impaired macrophage function [14, 17] . In the present cases, all 12 patients had a record of periodontal soft-and hard-tissue infection, which might have increased the chance of colonization by Aspergillus species during neutropenia. Kamma et al. [18] recently reported that Aspergillus and Candida species were found in significantly higher numbers and more frequently in smokers with advanced periodontitis. It is possible that the presence of oral infections, including periodontal disease, periapical foci, and decubitic ulcers of gingiva due to a misuse of the denture, may represent a new risk factor for invasive Aspergillus stomatitis.
All patients in the present study presented with persistent fever and у2 characteristic symptoms suggestive of invasive Aspergillus stomatitis. The most common symptoms were gingival pain and facial swelling, followed by excessive salivation. These symptoms are similar to those described in studies elsewhere [8] [9] [10] [11] . Although other studies [8, 9, 11] described that invasive oral aspergillosis initially developed in the palate or tongue and extended down to the hypopharynx, in the present cases oral lesions presented as solitary discoloration of marginal gingiva and spread to adjacent tissues, developing ulcers with gray pseudomembranes and necrotic alveolar bones. During its incipient stages, the infection is difficult to diagnose because stomatitis secondary to cytotoxic treatment and other bacterial or viral infections may hinder prompt recognition; however, lack of awareness of its varying presentations will almost certainly result in delayed diagnosis and treatment. When suspicious lesions are identified, biopsy is an essential procedure for the proper diagnosis of fungal infections. Diagnosis of invasive Aspergillus stomatitis in the present study was made by histopathological examination of oral tissue specimens and confirmed by microbiological examination of the same specimens. Diagnosis was made a median of 23 days (range, 14-38 days) after admission and a median of 11 days (range, 7-26 days) after the onset of neutropenia. Iwen et al. [19] documented that invasive aspergillosis frequently occurred in patients following a relatively short period of neutropenia (7-10 days), whereas Gerson et al. [1] reported that the infection manifested after the 12th day of profound neutropenia. In the present cases, invasive oral Aspergillus infection usually developed during the first 18 days, while patients were neutropenic. In 1 neutropenic patient, however, the diagnosis was made after a 26-day period of neutropenia. Therefore, patients at risk should be monitored carefully during neutropenia.
The survival rate of patients with invasive Aspergillus stomatitis in the present study was 83% (10 of 12 patients), which appears higher than for invasive aspergillosis presenting at other sites, including 50% for the skin [6] , 47% for the sinus [5] , 10% for the lung [20] , and 0% for the brain [3] . This improved outcome in our cases may relate to the fact that the oral lesions are easily identifiable, which allows for early diagnosis and treatment before significant dissemination occurs. The surviving 10 patients received both iv amphotericin B and surgical management. The 2 patients who died were treated with amphotericin B but did not undergo surgery, because of the poor recovery of pancytopenia along with the rapid progression of aspergillosis. Our previous in vitro susceptibility testing of oral Aspergillus isolates demonstrated that amphotericin B was active for both A. flavus and A. terreus with low MIC values [21] . Amphotericin B remained the mainstay of antifungal medication in the present cases, and surgery was effective in preventing the progression and reactivation of Aspergillus foci; however, survival of patients with invasive aspergillosis, even those treated with aggressive surgical intervention and amphotericin B, was dependent, in part, on the recovery of bone marrow function [6, 7, 9] .
In summary, these 12 cases extend the information on invasive oral aspergillosis. The high survival rate associated with this condition could be achieved with early diagnosis and aggressive therapy in addition to the improvement of the patient's hematologic status. Therefore, clinicians managing neutropenic patients with acute leukemia should recognize this infection as a distinctive type of invasive aspergillosis and should carry out prompt treatment to improve the outcome of this disease.
